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CRP showed the veno-aortic differences. Intense L-PGDS-immunoreactivity was 
detected in smooth muscle cells and extracellular matrix of the coronary arteries with 
early atherosclerosis and in the atheromatous vein graft, but the level was faint in the 
native coronary artery with marked atherosclerosis. The expression profiles of L-PGDS 
mRNA were consistent with the immunohistochemical findings. 
Conclusion: L-PGDS is actively secreted from the early atherosclerotic plaque in the cor- 
onary circulation. Serum L-PGDS is useful as a marker of coronary atherosclerosis. 
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847-2 Comparative Effects of Statin and Fibrate on Nitric 
Oxide Bioactivity and Markers of Inflammation in 
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Gachon Medical School, Incheon, South Korea 
Background: We mvestigated whether most commonly used lipid-lowering therapies- 
statins and fibrate improve nitric oxide (NO) bioactivity and reduce serological markers of 
inflammation and whether these therapies-induced reduction in markers of inflammation 
is mediated by improvement in NO bioactivity or lipoprotein changes. 
Methods For 8 weeks, we administered simvastatin 20 mg or fenofibrate 200 mg daily 
to each 27 randomly selected patients with hypercholesterolemia and coronary artery 
disease or pure hypertriglyceridemia, respectively. Data= mean&EM and median (25%. 
75%). 
Results Both therapies signiftcantly changed lipoprotein levels from the respective 
baseline levels. As expected, simvastatin significantly lowered TC and LDL-C more and 
fenofibrate increased TG and 
HDL-C more than either therapy. Simvastatin and fenoflbrate significantly improved the 
percent flow-mediated dilator response to hyperemia (FMD) from 3.3QO.45 to 6.06iO.47 
and from 5.20*0.35 to 6.38kO.33, respectively (each PcO.OOl), however, simvastatin sig- 
nificantly improved FMD and reduced plasma levels of malondialdehyde (MDA), a 
marker of free radical from 1.95+0.13 to 1.60*0.15 uM (PcO.01) to greater extent. Both 
therapies did not change plasma levels of nitrate. Slmvastatin and fenofibrate signifi- 
cantly lowered plasma levels of TNF-a from 3.31eO.35 to 2.67kO.27 pg/ml and from 
1.61~0.10 to 1.43*0.10 pgiml (each P<O.Ol). respectively and serum levels of CRP from 
0.59 to 0.16 (P<O.OOl) and from 0.17 to 0.11 (P=O.280), respectively, however, simvas- 
tatln significantly lowered CRP levels to greater extent than fenofibrate. There were sig- 
nificant inverse correlation between LDL cholesterol and flow-mediated dilation percent 
(r=-0.342. P=O.O09). Of interest, there were significant inverse correlations between flow- 
mediated dilation percent and TNF-u levels (r=-0.293, P=O.O35). However, no significant 
correlations between lipoprotein levels and levels of inflammation markers ware deter- 
mined. 
Conclusions; Simvastatin and fenofibrate significantly improved NO bioactivity through 
different biological mechanisms on lipoproteins and markers of free radical and inflam- 
mation. 
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Background: Case control studies evaluating the 677CT polymorphism of methylenetet- 
rahydrofolate reductase (MTHFR) as an independent genetic risk factor of coronary 
artery disease have produced contradictory conclusions. The reason could be that its 
association to all other polymorphisms of the enzymes related to homocysteine metabo- 
lism has never been taken into account. These polymorphisms are the 1298 AC, 2756 
AG and 66 AG substitutions #I the genes of MTHFR. methionine synthase (MTR) and 
methionine synthase reductase (MTRR) respectwely. 
Methods We investigated the individual and combined effects of these 4 polymorphisms 
and of nutritional (vitamin B6, vitamin B12, folates) and metabolic factors (cystathionine, 
methylmalonate, cystatine-C) relied with the plasma homocystein (t-Hcys) level in case 
control study including 108 patients and 130 controls. 
Results The plasma t-Hcys was higher in patients than in controls (PcOOl). It was also 
higher in MTHFR 677 lT, than in 677 CC and 677 CT, II? controls, but not in patients. 
Cystatin-C, marker of glomerular filtratton was the single independent determinant of 
increased t-Hcys of patients (P = 0.04), m multiple regression analysts. taking also into 
account folates. vitamin 86 and 812, cystationme and methylmalonic acid. The upper 
quartile of t-Hcys (>10.5 wmol/l) and MTR 2756 AGIGG genotype were significant inde- 
pendent risk factors of coronary artery disease with respective Odds ratios of 3.0 (95 % 
Cl: 1.7-5.3. P=O.O002) and of 2.8 (95% Cl: 1.3-6.0, P=O.Olll). By contrast. the combma- 
tion of MTHFR 677 CT/MTR 2756 AG, MTHFR 677 CC/1298 AC and MTHFR 677 CT/ 
1298AA were protective, with Odd ratios of 0.13, 0.48 and 0.34, respectively. 
Conclusion: MTR 2756 AG genotype considered alone is a potent risk factor of coronary 
artery disease while it becomes protective in association with MTHFR 677 CT genotype. 
Increase of t-Hcys IS rather Influenced by glomerular filtration than by genetic and nutri- 
tlonal factors. Our study Illustrates the necessity to evaluate the relative risk generated by 
t-Hcys by considering the interaction of all genetic nutritional and metabolic potential 
determinants rather than by evaluating independently each one. 
11:15 a.m. 
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Anna Svatikova Robert Walk. Paola Lanfranchi, Mark J. Magera. Joseph P. McConnell, 
Virend K. Somers, Mayo Clinic, Rochester, MN 
Background: Obstructwe sleep apnea (OSA) has been increasingly lknked to cardiovas- 
cular diseases and endothelial dysfunction. Methyl&d arginines, endogenous inhibitors 
of nitric oxide synthase, have been implicated as a possible mechanism for endothelial 
dysfunction in cardiovascular diseases. We tested the hypothesis that repetitive severe 
hypoxemia resulting from OSA would increase serum asymmetrically methyl&d argin- 
ines (asymmetric dimethylarginine, ADMA. and monomethylarginine, L-NMMA). 
Methods: We studied 10 men with newly diagnosed OSA who were free of other dis- 
eases, had never been treated for OSA, and were taking no medications. Measurements 
were made before and after 5 hours of untreated OSA, and again after 4 hours of acute 
continuous positive allway pressure &PAP) treatment. We compared methyl&d argin- 
ine measurements I” these patients to measurements obtained at similar times in 10 
matched control sublects. 
Results: Baseline ADMA and L-NMMA levels before sleep were similar in the OSA and 
control group. ADMA and L-NMMA levels increased significantly (from 13.9iO.7 to 
16.1-0.5, P=O.O3. and from 4.6r0.2 to 5.5rO.i nglml. P=O.O02. respectively) in the OSA 
group after 5 hours of untreated OSA. The increase in ADMA and L-NMMA was blunted 
by acute CPAP treatment. There was a significant correlation between Apnea-Hypopnea 
Index and increases in ADMA (R=0.58, P=O.O077) and L-NMMA (R=0.63, P=O.O028). In 
the control group, methylated arginine levels were stable throughout the night. 
Conclusions: OSA is associated with acute elevation of ADMA and L-NMMA. This 
increase is blunted by effective CPAP treatment. Increased asymmetrlcally methyl&d 
arginines may be a potential mechanw.m to explain the association between OSA and 
cardiovascular disease. 
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Background: Available data suggest that hemoglobin Ale (HbAlc) levels may be 
related to cardiovascular risk in the general non-diabetic population. We sought to test 
this hypothesis prospectively in a cohort of women without overt cardiovascular disease. 
Methods: We conducted a nested 1:2 cazcontrol study in the Women’s Health Study 
cohort. We Identified 464 cases of incident myocardial infarction, stroke, or coronary 
revascularization and 928 controls who remained free of cardiovascular events at the 
time of case diagnosis. The mean follow-up was 7 years. 
Results: 136 of the overall study population had a history of diabetes at enrollment or an 
overtly elevated baseline HbAlc (~-6.40%) and were excluded from the primary analyses. 
Among women without diabetes or an elevated baseline HbAlc, baseline mean levels of 
HbAlc were significantly higher among future cardiovascular cases than controls (5.47% 
* 0.27 vs 5.37% t 0.22; p<O.OOOl). The crude relative risks (RR) of incident cardiovascu- 
lar events for increasing quartiles of HbAlc were 1, 0.98, 1.33, and 2.25 (95% Cl for 
highest vs lowest quartile 1.59-3.18). HbAlc levels were significantly correlated with sev- 
eral other traditional cardiovascular risk factors, including age, body mass index, systolic 
blood pressure, C-reactive protein, and total cholesterol: high density lipoprotein-choles- 
terol ratio. In fully adjusted models the predictive effect of HbAlc was attenuated and not 
significant (RR = 1 .OO for top vs bottom quartile, 95% Cl 0.65-l .54). In contrast. in the 
population including women with diabetes at enrollment, diabetes (RR 4.97, 95% Cl 
2.81-8.77) remained a strong Independent determinant of cardiovascular risk I” fully 
adjusted analyses, while HbAl c levels did not (RR = 1 .ll for top vs bottom quartile, 95% 
Cl 0.73-1.71). 
Conclusion: HbAlc is associated with future cardiovascular risk among non-diabetic 
women, but this relationship is largely attributable to a strong correlation with other car- 
diovascular risk factors. In contrast, diabetes is a strong independent determinant of car- 
diovascular risk, even after adjustment for HbAl c levels. 
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Salman Ashfaq, Sean C. Beinart, Jerome L. Abramson, Steven D. Rhodes, Claudine 
Jurkovitz, Viola Vaccarino, Jovonne K. Williams, Dean P. Jones. Arshed A. Quyyuml, 
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Background: Although trials of antioxidant therapy for cardiovascular disease in 
humans have not shown long-term benefit, there remams evidence in animals for the role 
of oxidative stress in the pathogen&s of atherosclerosis. The plasma redox state of glu- 
tathlone (Eh GSH/GSSG) has been shown to be a novel marker of oxldative stress in 
humans. We hypothesized that in Eh GSH/GSSG and endothelial dysfunction would both 
correlate with the presence of early atherosclerosis in humans. 
Methods: We evaluated brachial artery flow-mediated dilation (FMD) and common 
carotid artery intlma media thickness (CIMT) in 40 adults with no clinical atherosclerotic 
disease. Plasma glutathione (GSH), oxidized glutathione (GSSG). Eh GSH/GSSG, and 
FMD were correlated with CIMT. 
Results: There was an inverse correlation between CIMT and FMD (r = - 0.43, p- 0.005). 
